0 585

Cited 3 times in

Clinical impact of early recovery of peripheral blood absolute lymphocyte count after frontline autologous stem cell transplantation for diffuse large B-cell lymphoma

 Yundeok Kim  ;  Soo‐Jeong Kim  ;  June‐Won Cheong  ;  Hyunsoo Cho  ;  Haerim Chung  ;  Jung Yeon Lee  ;  Ji Eun Jang  ;  Yoo Hong Min  ;  Jin Seok Kim 
 HEMATOLOGICAL ONCOLOGY, Vol.35(4) : 465-471, 2017 
Journal Title
Issue Date
Adult ; Aged ; Disease-Free Survival ; Female ; Hematopoietic Stem Cell Transplantation/methods* ; Humans ; Lymphocyte Count/methods* ; Lymphoma, Large B-Cell, Diffuse/drug therapy* ; Male ; Middle Aged ; Prognosis ; Retrospective Studies ; Transplantation Conditioning/methods* ; Transplantation, Autologous/methods* ; Young Adult
absolute lymphocyte count ; diffuse large B-cell lymphoma ; frontline autologous stem cell transplantation ; prognostic marker
We conducted a retrospective study to evaluate the clinical impact of an early recovery of posttransplant absolute lymphocyte count (ALC) on the outcome of frontline autologous stem cell transplantation (ASCT) for diffuse large B-cell lymphoma (DLBCL). We reviewed 65 DLBCL patients who underwent frontline ASCT after primary chemotherapy based on cyclophosphamide, doxorubicin, vincristine, and prednisone. A receiver operating characteristic analysis was performed to determine the optimal cut point (0.4 × 109 /L) for an ALC at 15 days after ASCT (ALC-15). Both event-free survival and overall survival rates of the higher-ALC-15 group were significantly better than those of the lower-ALC-15 group (event-free survival, P = .008; overall survival, P = .013). The infused CD34+ cell count was significantly associated with the recovery of ALC-15 (>0.4 × 109 /L) after ASCT (P = .028). A multivariate analysis confirmed that a higher infused CD34+ cell dose (>5.0 × 106 cells/kg) was an independent factor affecting an early recovery of ALC after ASCT (odds ratio, 4.145; 95% confidence interval, 1.106-15.528; P = .035). In conclusion, an early recovery of ALC after ASCT can be regarded as a good prognostic marker in patients with DLBCL who have undergone frontline ASCT. We found that the infused CD34+ cell dose for ASCT was associated with the recovery of ALC.
Full Text
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Soo Jeong(김수정) ORCID logo https://orcid.org/0000-0001-8859-3573
Kim, Yun Deok(김윤덕) ORCID logo https://orcid.org/0000-0002-5336-7936
Kim, Jin Seok(김진석) ORCID logo https://orcid.org/0000-0001-8986-8436
Min, Yoo Hong(민유홍) ORCID logo https://orcid.org/0000-0001-8542-9583
Lee, Jung Yoen(이정연)
Jang, Ji Eun(장지은) ORCID logo https://orcid.org/0000-0001-8832-1412
Cheong, June-Won(정준원) ORCID logo https://orcid.org/0000-0002-1744-0921
Chung, Hae Rim(정해림) ORCID logo https://orcid.org/0000-0002-7926-9285
Cho, Hyunsoo(조현수) ORCID logo https://orcid.org/0000-0003-2651-6403
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.